专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US06458762B1 Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis 失效
标题翻译：治疗性使用血红蛋白来维持组织活力并减少再狭窄
公开(公告)号：US06458762B1
公开(公告)日：2002-10-01
申请号：US08350204
申请日：1994-12-02
申请人： Jack E. McKenzie , Kenneth E. Burhop
发明人： Jack E. McKenzie , Kenneth E. Burhop
IPC分类号： A61K3816
CPC分类号： A61K38/42 , A61K2300/00
摘要： Administration of low doses of hemoglobin minimizes damage to the myocardium after blockage and significantly reduces reperfusion injury. Hemoglobin exerts a pharmacological effect by increasing perfusion and blocking the molecular events leading to permanent injury following an ischemic episode. Additional benefits include a reduction in the number of post-ischemic arrhythmias, reduction in the incidence of restenosis, and improved contractile function in the area of risk.
摘要翻译：低剂量血红蛋白的施用可使堵塞后对心肌的损伤最小化，并显着降低再灌注损伤。血红蛋白通过增加灌注并阻断导致缺血发作后永久性损伤的分子事件而发挥药理作用。额外的好处包括减少缺血后心律失常的数量，减少再狭窄的发生率，改善风险领域的收缩功能。

22. 发明授权

US06432917B1 Inhibitor of stem cell proliferation and uses thereof 失效
标题翻译：干细胞增殖抑制剂及其用途
公开(公告)号：US06432917B1
公开(公告)日：2002-08-13
申请号：US08477669
申请日：1995-06-07
申请人： Vladimir Kozlov , Irena Tsyrlova
发明人： Vladimir Kozlov , Irena Tsyrlova
IPC分类号： A61K3816
CPC分类号： A61K38/42 , A61K39/39 , C07K14/4703 , C07K14/475 , C07K14/52 , C07K14/805 , A61K2300/00
摘要： Disclosed and claimed are methods for the isolation and use of stem cell inhibiting factors for regulating the abnormal stem cell cycle and for accelerating the post-chemotherapy peripheral blood cell recovery. Also disclosed and claimed are the inhibitors of stem cell proliferation.
摘要翻译：公开和要求的是用于分离和使用干细胞抑制因子以调节异常干细胞周期和加速化疗后外周血细胞恢复的方法。还公开并要求保护的是干细胞增殖的抑制剂。

23. 发明授权

US06423684B1 WD-40 derived peptides and uses thereof 失效
标题翻译： WD-40衍生的肽及其用途
公开(公告)号：US06423684B1
公开(公告)日：2002-07-23
申请号：US08487072
申请日：1995-06-07
申请人： Daria Mochly-Rosen , Dorit Ron
发明人： Daria Mochly-Rosen , Dorit Ron
IPC分类号： A61K3816
CPC分类号： C07K14/00 , C07K5/1024 , C07K14/4722 , C07K14/705
摘要： The present invention relates to a polypeptide composition effective to alter the activity of a first protein that interacts with a second protein, where the second protein contains at least one WD-40 region. The polypeptides of the present invention typically have between 4 and 50 amino acids whose sequence is the same as a sequence of the same length in the WD-40 region of the second protein. The invention further includes a method of altering the activity of the above described first protein. In one embodiment of the invention the polypeptide composition is effective to alter the activity of a protein kinase C, where the protein kinase C interacts with a second protein, and the second protein contains at least one WD-40 region (e.g., RACK1).
摘要翻译：本发明涉及有效改变与第二种蛋白质相互作用的第一种蛋白质的活性的多肽组合物，其中第二种蛋白质含有至少一种WD-40区域。本发明的多肽通常具有4至50个氨基酸，其序列与第二蛋白质的WD-40区域中相同长度的序列相同。本发明还包括改变上述第一种蛋白质的活性的方法。在本发明的一个实施方案中，多肽组合物有效地改变蛋白激酶C的活性，其中蛋白激酶C与第二蛋白质相互作用，第二蛋白质含有至少一个WD-40区域（例如RACK1）。

24. 发明授权

US06384015B1 Selective lysis of malaria infected erythrocytes 失效
标题翻译：疟疾感染红细胞的选择性裂解
公开(公告)号：US06384015B1
公开(公告)日：2002-05-07
申请号：US08831993
申请日：1997-04-01
申请人： Shervin K. Pishevar
发明人： Shervin K. Pishevar
IPC分类号： A61K3816
CPC分类号： A61K38/1703 , Y02A50/411
摘要： The invention provides methods and compositions for inhibiting the development of intracellular parasites by treating such cells with an effective concentration of a magainin, PGLa or XPF peptide under conditions whereby the development of the parasite in the cell is inhibited. The targeted parasites have been found to increase in the accessibility of the plasma membrane of said cell to the peptide, and particularly, to effect an increase in the cytopathic, especially lytic, sensitivity of the cell to the peptide. In one application, the invention provides methods for treating blood infected with a Plasmodium species, by contacting the blood with magainin 2 under conditions whereby the development of the Plasmodium in the infected erythrocytes is inhibited and the infected erythrocytes evidence relatively increased cytolytic sensitivity to the magainin.
摘要翻译：本发明提供了通过在有效浓度的magainin，PGLa或XPF肽处理这种细胞的条件下抑制细胞内寄生虫的发育的方法和组合物，由此细胞中寄生虫的发育受到抑制。已经发现靶向的寄生虫增加所述细胞的质膜对肽的可及性，特别是增加细胞对肽的细胞病变，特别是溶解的敏感性。在一个应用中，本发明提供了用于治疗感染疟原虫物种的血液的方法，其通过使血液与马卡宁2接触，其中感染的红细胞中的疟原虫的发育被抑制并且感染的红细胞证实对magainin的溶细胞敏感性相对增加。

25. 发明授权

US06365570B1 Pharmaceutical and diagnostic use of Serum Amyloid P component 失效
标题翻译：血清淀粉样蛋白P成分的药物和诊断用途
公开(公告)号：US06365570B1
公开(公告)日：2002-04-02
申请号：US09284219
申请日：1999-06-18
申请人： Cornelis Petrus Maria Van Kessel , Johannes Antonius Gerardus Van Strijp
发明人： Cornelis Petrus Maria Van Kessel , Johannes Antonius Gerardus Van Strijp
IPC分类号： A61K3816
CPC分类号： C07K14/4711 , A61K38/00
摘要： The invention relates to the new use of Serum Amyloid P component (SAP) and/or endotoxin-binding fragments thereof for the preparation of a pharmaceutical composition for neutralizing lipopolysaccharide and particularly for the treatment of sepsis. The invention further relates to a diagnostic method for demonstrating the presence of endotoxin in blood or blood fractions, such as serum or plasma.
摘要翻译：本发明涉及血清淀粉样蛋白P组分（SAP）和/或其内毒素结合片段的新用途，用于制备用于中和脂多糖的药物组合物，特别是用于治疗败血症。本发明还涉及用于证明血液或血液部分如血清或血浆中内毒素的存在的诊断方法。

26. 发明授权

US06358919B1 Polymer compounds comprising glycosphingosine 失效
标题翻译：含有鞘氨醇的高分子化合物
公开(公告)号：US06358919B1
公开(公告)日：2002-03-19
申请号：US09109870
申请日：1998-07-06
申请人： Osamu Kanie , Chi-Huey Wong , Hiroshi Kamitakahara
发明人： Osamu Kanie , Chi-Huey Wong , Hiroshi Kamitakahara
IPC分类号： A61K3816
CPC分类号： A61K47/645
摘要： A polymer compound or a salt thereof which comprises a biodegradable polymer such as polyglutamic acid acetylated at N-terminal thereof containing a glycosphingolipid such as lysoganglioside GM3, and which exerts antiviral activity against variety of viruses and is useful as an active ingredient of a medicament.
摘要翻译：一种高分子化合物或其盐，其包含生物降解性聚合物，例如在其N末端乙酰化的聚谷氨酸，其含有鞘糖脂如溶血性神经节苷脂GM3，并且针对各种病毒发挥抗病毒活性，并且可用作药物的活性成分。

27. 发明授权

US06352973B1 Bone stimulating factor 失效
标题翻译：骨刺激因子
公开(公告)号：US06352973B1
公开(公告)日：2002-03-05
申请号：US08986627
申请日：1997-12-08
申请人： Cherk Shing Tam
发明人： Cherk Shing Tam
IPC分类号： A61K3816
CPC分类号： C07K14/51 , A61K38/00 , C07K2319/00
摘要： Polypeptides which stimulate bone growth, associated nucleotide sequences, methods of preparation and use, antibodies and kits are disclosed.
摘要翻译：公开了刺激骨生长的多肽，相关核苷酸序列，制备和使用方法，抗体和试剂盒。

28. 发明授权

US06326351B1 Bacillus thuringiensis CryET33 and CryET34 compositions and uses therefor 有权
标题翻译：苏云金芽孢杆菌CryET33和CryET34组合物及其用途
公开(公告)号：US06326351B1
公开(公告)日：2001-12-04
申请号：US09147992
申请日：1999-07-21
申请人： William P. Donovan , Judith C. Donovan , Annette C. Slaney
发明人： William P. Donovan , Judith C. Donovan , Annette C. Slaney
IPC分类号： A61K3816
CPC分类号： G01N33/56911 , C07K14/325 , G01N2333/325 , Y10S435/81 , Y10S530/825 , Y10T436/143333
摘要： Disclosed are Bacillus thuringiensis strains comprising novel crystal proteins which exhibit insecticidal activity against coleopteran insects including red flour beetle larvae (Tribolium castaneum) and Japanese beetle larvae (Popillia japonica). Also disclosed are novel B. thuringiensis crystal toxin genes, designated cryET33 and cryET34, which encode respectively the coleopteran-toxic proteins, CryET33 (29-kDa) crystal protein, and CryET34 (14-kDa) crystal protein. Also disclosed are methods of making and using transgenic cells comprising the novel nucleic acid sequences of the invention.
摘要翻译：公开了包含对鞘翅目昆虫具有杀虫活性的新型晶体蛋白的苏云金芽孢杆菌菌株，包括红粉甲虫幼虫（Tribolium castaneum）和日本甲虫幼虫（Popillia japonica）。还公开了分别编码鞘翅目毒素蛋白CryET33（29-kDa）晶体蛋白和CryET34（14-kDa）晶体蛋白的新型苏云金芽孢杆菌晶体毒素基因，命名为cryET33和cryET34。还公开了制备和使用包含本发明的新核酸序列的转基因细胞的方法。

29. 发明授权

US06200953B1 Relaxin analogs and derivatives compositions 有权
标题翻译：松弛素类似物和衍生物组合物
公开(公告)号：US06200953B1
公开(公告)日：2001-03-13
申请号：US09158706
申请日：1998-09-22
申请人： Christian Schwabe , Elaine Unemori
发明人： Christian Schwabe , Elaine Unemori
IPC分类号： A61K3816
CPC分类号： C07K14/64 , A61K38/2221
摘要： The present invention relates to a relaxin analogs and derivatives, and uses thereof. The present invention further relates to compositions comprising a relaxin analogs and derivatives, and relaxin wherein such composition exhibits an additive or synergistic effect.
摘要翻译：本发明涉及松弛素类似物及其衍生物及其用途。本发明还涉及包含松弛素类似物和衍生物的组合物和松香素，其中这种组合物显示出添加剂或协同效应。

30. 发明授权

US06200952B1 Combination therapy method for treating chronic hepatitis B 失效
标题翻译：治疗慢性乙型肝炎的联合治疗方法
公开(公告)号：US06200952B1
公开(公告)日：2001-03-13
申请号：US08363558
申请日：1994-12-22
申请人： David L. Horwitz
发明人： David L. Horwitz
IPC分类号： A61K3816
CPC分类号： A61K38/21 , A61K38/2292 , A61K2300/00
摘要： The present invention is aimed at augmenting the success rate of using thymosin in treatment of chronic hepatitis B, by employing a combination therapy using thymosin with antiviral agents which are effective in inhibiting DNA synthesis or DNA polymerase during replication of the hepatitis B virus.
摘要翻译：本发明旨在通过使用胸腺素与乙肝病毒复制期间有效抑制DNA合成或DNA聚合酶的抗病毒剂的组合疗法来增加使用胸腺素治疗慢性乙型肝炎的成功率。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式